JamesRalphRigasMDFACP

Oncology • Hanover, NH

Hematologic Oncology, Thoracic Cancer

Professor of Medicine, Geisel School of Medicine at Dartmouth

Join to view full profile

Dr. Rigas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Rigas' full profile

Already have an account?

Office
3 Mulherrin Farm Rd
Hanover, NH 03755
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1990
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1984 - 1988
MCP-Hahnemann College of MedicineClass of 1984

Certifications & Licensure

NH State Medical License 1995 - 2021
VT State Medical License 1995 - 2004

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer Start of enrollment: 1998 Nov 01
Terminated
Phase 1, Phase 2
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2005 May 01
Completed
Phase 3
A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer Start of enrollment: 2001 Aug 01
Terminated
Phase 1, Phase 2
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 4
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer Start of enrollment: 2000 Feb 01
Completed
Phase 1
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin Start of enrollment: 2011 Jan 16
Completed
Phase 3
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer Start of enrollment: 2010 Jul 01
Completed
Join now to see all

Publications & Presentations

PubMed

1 citations
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer.
Matthew B. Schabath, Tapashi Dalvi, Hongyue A Dai, Alan Crim, Anita Midha, Norah J. Shire, Nicholas T. Gimbrone, Jill Walker, Danielle Greenawalt, David Lawrence, J. R...> ;Cancer Management and Research. 2019 Nov 7
40 citations
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Filippo de Marinis, Yi-Long Wu, Gilberto de Castro, Gee-Chen Chang, Yuh Min Chen, Byoung Chul Cho, Helano C. Freitas, Liyan Jiang, Sang We Kim, Claudio Martin, Giulio ...> ;Future Oncology. 2019 Jul 24
8 citations
Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non–Small-Cell Lung Cancer in the United States
Ronan J. Kelly, Ralph M Turner, Yen-Wen Chen, J. Rigas, Ancilla W. Fernandes, Sudeep Karve> ;Journal of Oncology Practice. 2019 Jun 25
4 citations
A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer
Konstantin H. Dragnev, Jeremy D. Whyman, Cynthia K. Hahn, Peter E. Kebbekus, Sarah F. Kokko, Sunil Bhatt, James R. Rigas> ;Journal of Thoracic Disease. 2018 Sep 1
520 citations
An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer
David Planchard, Benjamin Besse, Harry J.M. Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S. Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novel...> ;The Lancet. Oncology. 2016 Jul 1
15 citations
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.
Lakshmi Nayak, Lisa M. DeAngelis, H. Ian Robins, Ramaswamy Govindan, Shirish M. Gadgeel, Karen Kelly, James R. Rigas, David M. Peereboom, Steven S. Rosenfeld, Alona Mu...> ;Cancer. 2015 Dec 1
22 citations
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non...
Hongbin Chen, Manuel Modiano, Joel W. Neal, Julie R. Brahmer, James R. Rigas, Robert M. Jotte, Natasha B. Leighl, Jonathan W. Riess, Calvin J. Kuo, Liming Liu, B. Gao,...> ;British Journal of Cancer. 2014 Feb 4
89 citations
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testi...
Monic Roengvoraphoj, Gregory J. Tsongalis, Konstantin H. Dragnev, James R. Rigas> ;Cancer Treatment Reviews. 2013 Dec 1
76 citations
Quantitative Phosphoproteomic Profiling of Human Non-Small Cell Lung Cancer Tumors
Devin K. Schweppe, James R. Rigas, Scott A. Gerber> ;Journal of Proteomics. 2013 Oct 8
6 citations
VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.
Xiuyi Zhi, Wen Gao, Baohui Han, Yue Yang, Hui Li, Deruo Liu, Changli Wang, Gong Min, Hao Long, James R. Rigas, Mark Carey, Thierry Jahan, Amanda Sammann, Joseph A. Rez...> ;Journal of Thoracic Disease. 2013 Sep 22
7 citations
Trimodality Therapy for Stage II-III Carcinoma of the Esophagus: A Dose-Ranging Study of Concurrent Capecitabine, Docetaxel, and Thoracic Radiotherapy
Matthew D. Wood, Bassem I. Zaki, Stuart R. Gordon, John E. Sutton, Mikhail Lisovsky, Jiang Gui, Jeffrey A. Bubis, Konstantin H. Dragnev, James R. Rigas> ;Journal of Thoracic Oncology. 2013 Apr 1
16 citations
Adenocarcinoma Contains More Immune Tolerance Regulatory T-cell Lymphocytes (Versus Squamous Carcinoma) in Non-small-Cell Lung Cancer
Candice C. Black, Mary Jo Turk, Konstantin H. Dragnev, James R. Rigas> ;Lung. 2013 Mar 15
15 citations
Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Jonathan D. Marotti, C B S Mary Schwab, Nancy J. McNulty, James R. Rigas, Peter A. DeLong, Vincent A. Memoli, Gregory J. Tsongalis, Vijayalakshmi Padmanabhan> ;Diagnostic Cytopathology. 2013 Jan 1
29 citations
A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients
Tian Ma, Alexander D. Fuld, James R. Rigas, Anne E. Hagey, Gary Gordon, Ethan Dmitrovsky, Konstantin H. Dragnev> ;Chemotherapy. 2012 Jan 1
167 citations
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Trevor J Bayliss, Jeff T Smith, Michael W. Schuster, Konstantin H. Dragnev, James R. Rigas> ;Expert Opinion on Biological Therapy. 2011 Nov 3
46 citations
Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models
Konstantin H. Dragnev, Tian Ma, Jobin Cyrus, Fabrizio Galimberti, Vincent A. Memoli, Alexander M. Busch, Gregory J. Tsongalis, Marc Seltzer, David W. Johnstone, Cherie...> ;Cancer Prevention Research. 2011 Jun 1
A window-of-opportunity trial of vorinostat (V) in patients with resectable non-small cell lung cancer (NSCLC).
Dragnev KH, Ma T, Galimberti F, Erkmen CP, Memoli V, Nugent W, Rigas JR, Johnstone D, Frandsen A, Simeone S, Czum J, Li H, DiRenzo J, Freemantle S, Dmitrovsky E> ;J. Clin. Oncol.. 2011-05-20
52 citations
Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small ...
Ming-Sound Tsao, Akira Sakurada, Keyue Ding, Sarit Aviel-Ronen, Olga Ludkovski, Ni Liu, Aurélie Le Maître, David R. Gandara, David H. Johnson, James R. Rigas, Lesley S...> ;Journal of Thoracic Oncology. 2011 Jan 1
35 citations
Pemetrexed in advanced non-small-cell lung cancer.
Alexander D. Fuld, Konstantin H. Dragnev, James R. Rigas> ;Expert Opinion on Pharmacotherapy. 2010 May 6
7 citations
A Dose Escalation Trial of Biweekly Docetaxel and Gemcitabine with Filgrastim or Pegfilgrastim for the Treatment of Patients with Advanced Solid Tumors
Konstantin H. Dragnev, Steven B. Hardin, J. Marc Pipas, Thomas H. Davis, James R. Rigas> ;Chemotherapy. 2010 Apr 20
45 citations
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Tianhong Li, Liawaty Ho, Bilal Piperdi, Tarek N. Elrafei, Fernando Camacho, James R. Rigas, Roman Perez-Soler, Rasim Gucalp> ;Lung Cancer. 2010 Apr 1
85 citations
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Ca...
Helen J. Ross, George R. Blumenschein, Joseph Aisner, Nevena Damjanov, Afshin Dowlati, Jennifer Garst, James R. Rigas, Michael Smylie, Habib Hassani, Kimberly E. Allen...> ;Clinical Cancer Research. 2010 Mar 15
110 citations
Lung cancer in a U.S. population with low to moderate arsenic exposure.
Julia E. Heck, Angeline S. Andrew, Tracy Onega, James R. Rigas, Brian P. Jackson, Margaret R. Karagas, Eric J. Duell> ;Environmental Health Perspectives. 2009 Jul 2
Association between triglyceride (TG) levels, other clinical characteristics, and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with er...
Dragnev KH, Cyrus JC, Rigas JR, DiSalvo WM, Dmitrovsky E> ;J. Clin. Oncol.. 2009-05-20
Dose-ranging study of the combination of paclitaxel poliglumex and pemetrexed in advanced non-small cell lung cancer (NSCLC).
Slagle BM, Rigas JR, Dragnev KH, Williams I, DiSalvo W, Engman C, Lipe B, Simeone S> ;J. Clin. Oncol.. 2009-05-20
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
International Association for the Study of Lung Cancer
Member